http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients
Chien, Tsu-Ming,Lu, Yen-Man,Geng, Jiun-Hung,Huang, Tsung-Yi,Ke, Hung-Lung,Huang, Chun-Nung,Li, Ching-Chia,Chou, Yii-Her,Wu, Wen-Jeng,Huang, Shu-Pin Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.3
Background: The prevalence of prostate cancer (PCa) has been increasing in recent years. Treatment strategies are largely based on the results of bone scan screening. Therefore, our aim was to investigate predictors of positive bone metastasis in newly diagnosed PCa patients. Materials and Methods: After extensive review, 336 consecutive patients newly diagnosed with PCa between April 2010 and November 2013 at our institution were enlisted in the study. Patients were divided into two groups according to bone scan results. Univariate analyses (Chi-square test for discrete variables and independent t-test for continuous variables) were applied to determine the potentially significant risk factors associated with distant bone metastasis. Binary logistic regression analyses were used to further investigate the influence of these factors on bone metastasis. Results: The patient mean age was $71.9{\pm}8.6years$ (range: 48 to 94 years). The mean prostate specific antigen (PSA) level and biopsy Gleason score were $260.2{\pm}1107.8ng/mL$ and $7.4{\pm}1.5$, respectively. The body mass index (BMI) for the series was $24.5{\pm}3.4kg/m^2$. Sixty-four patients (19.0%) had a positive bone scan result. Patients with positive bone scan results had a significantly lower BMI ($23.3{\pm}3.5$ vs. $24.8{\pm}3.3$; p=0.003), a higher Gleason score ($8.5{\pm}1.1$ vs. $7.1{\pm}1.5$; p < 0.001), and a higher PSA level ($1071.3{\pm}2337.1$ vs. $69.4{\pm}235.5$; p < 0.001) than those without bone metastasis. Multivariate logistic regression analysis employing the above independent predictors demonstrated that a Gleason score of ${\geq}7$, clinical stage ${\geq}T3$, $BMI{\leq}22kg/m^2$, and an initial PSA level of ${\geq}20ng/mL$ were all independent predictors of bone metastasis. Conclusions: A bone scan might be necessary in newly diagnosed PCa patients with any of the following criteria: clinical stage T3 or higher, a Gleason score of 7 or higher, BMI equal to or less than 22, and a PSA level of 20 or higher.
Magnetic Properties and Microscopic Structures of Ultrathin Co/p3 × p3 − R30˚-Ag/Si(111) Films
Jyh-Shen Tsay,Tsu-Yi Fu,Chih-Kuei Kao,Xiao-Lan Huang,Jyh-Ron Shue,Wei-Hsiang Chen,Yeong-Der Yao,구현주 한국물리학회 2013 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.62 No.12
Combined scanning tunneling microscopy and surface magneto-optic Kerr effect studies were employedto study the relation between magnetic properties and the microscopic interfacial structuresof ultrathin Co/p3×p3−R30˚-Ag/Si(111) films. On the top of p3×p3−R30˚-Ag/Si(111), pureCo clusters formed without disrupting the p3 × p3 − R30˚ structure of the Ag buffer layer. Thegreat strain due to the large mismatch between Co and the substrate influenced the nucleation ofCo atoms to form large clusters. No magnetic hysteresis in the polar configuration was observed forfilms thinner than 10 monolayers. The easy axis of magnetization was in the surface plane. Cappingp3 × p3 − R30˚-Ag on top of the Si(111) surface before the deposition of the Co overlayerscan efficiently reduce the nonferromagnetic Co-Si compound to zero thickness. For Co coveragebetween 2.9 and 4.2 monolayers, a lower Curie temperature was observed in ultrathin films. Due tothe existence of a smooth interface between Co and the p3 × p3 − R30˚-Ag buffer, the coercivityfor Co/p3 × p3 − R30˚-Ag/Si(111) is smaller than that for Co/Si(111).
김성배,Yau Tsz Kok,Tran Van Thuan,Tsu-Yi Chao,Zhen Zhou Shen 한국유방암학회 2015 Journal of breast cancer Vol.18 No.4
Purpose: The goal of this registry was to collect patient characteristics and safety data from patients from the Asia-Pacific region with early breast cancer receiving adjuvant chemotherapy containing docetaxel (Taxotere®). Methods: This registry was open-label, international, longitudinal, multicenter, and observational in design and included a prospective group of consecutive early breast cancer patients with an intermediate-to-high risk of recurrence being treated with various docetaxel-based (anthracycline and non-anthracycline) adjuvant chemotherapy regimens during 2009–2013 in real-world clinical settings. Results: The analysis included 1,712 patients, 79% of whom received docetaxel-based, anthracycline-containing regimens, while 21% received non-anthracycline-containing regimens. Patients receiving adjuvant docetaxel-based chemotherapy were followed for 1.5 years. Chemotherapy-related adverse events (AEs) were reported by 76.2% of patients (anthracycline-containing vs. nonanthracycline- containing regimens: 76.8% vs. 74.1%). Serious AEs were reported in 12% of patients (12.3% vs. 10%). National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or higher neutropenia was reported in 20% of patients (21.6% vs. 13.9%), leukopenia in 7.4% of patients (5.4% vs. 14.8%), and vomiting in 1.6% of patients (1.8% vs. 0.6%). Treatment-related death was reported in 27 patients (1.6%), while only 3% of patients had a relapse. Low-density lipoprotein cholesterol/high-density lipoprotein cholesterol (HDL-C) and total cholesterol/HDL-C ratios increased after chemotherapy. A clinically insignificant reduction of 1.9% in left ventricular ejection fraction, from 66.43 to 64.53, was observed 1.5 years after therapy was completed. Conclusion: The Asia-Pacific Breast initiative II registry identified a variety of important facts regarding patient population characteristics, disease epidemiology and treatment response for early breast cancer patients of the Asia-Pacific region receiving docetaxel-based chemotherapy. Docetaxel-based chemotherapy did not show any significant safety concerns for early breast cancer patients of the Asia- Pacific region, and thus may represent a safe adjuvant chemotherapy regimen for these patients.
He, Zuoli,Byun, Joon-Hyung,Zhou, Gengheng,Park, Byeong-Jin,Kim, Tae-Hoon,Lee, Sang-Bok,Yi, Jin-Woo,Um, Moon-Kwang,Chou, Tsu-Wei Elsevier 2019 Carbon Vol.146 No.-
<P><B>Abstract</B></P> <P>Stretchable conductive fibers have attracted significant attention due to their ability to be directly woven into or stitched onto fabrics, making them ideal for use in the design of integrated wearable strain sensors. Here, we report on a highly stretchable multi-walled carbon nanotube (MWCNT)/Thermoplastic Polyurethane (TPU) fiber produced via a wet spinning process. The effects of MWCNT content and alignment on the structural, mechanical, electrical and strain-sensing properties of the composite fibers were investigated. The highest conductivity (6.77 S cm<SUP>−1</SUP>), tensile strength (28 MPa) and maximum elongation at break (565%) were obtained by controlling the MWCNT content. Gauge factor (GF) values were also affected by the content and MWCNT alignment in the composite fibers, as these parameters determine the change in the effective contact area and number of conductive paths available during stretching. The well-aligned MWCNT/TPU fiber showed a high GF value of 5200. Wearable strain sensors capable of obtaining real-time mechanical feedback for various human motion detections with different GFs and working strain ranges could be realized by controlling the MWCNT concentrations in the TPU matrix.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Designing Redox-Stable Cobalt-Polypyridyl Complexes for Redox Flow Batteries
변혜령,( Chunzhen Yang ),( Goergiog Nikiforidis ),박지영,최종훈,( Yong Luo ),( Liang Zhang ),( Shi-cheng Wang ),( Yi-tsu Chan ),( Zhaomin Hou ),백무현,이윤호 한국공업화학회 2018 한국공업화학회 연구논문 초록집 Vol.2018 No.0
We developed rational strategies for exploiting two common principles in organometallic chemistry for enhancing the robustness of pseudo-octahedral Co-polypyridyl complexes. Namely, the spin-crossover between low and high-spin states and the chelation effect emerging from replacing three bidentate ligands with two tridentate analogues. Quantum chemical models are used to conceptualize our approach and make predictions that are tested against experiments by preparing prototype Co-complexes and profiling them as catholytes and anolytes. In good agreement with the conceptual predictions, very stable cycling performance over 600 charge cycles is found.
Kim, Sung Bae,Sayeed, Ahmed,Villalon, Antonio H,Shen, Zhen Zhou,Yau, Tsz Kok,Shah, Mazhar Ali,Hou, Meng Feng,Thuan, Tran Van,Ba, Duc Nguyen,Chao, Tsu-Yi Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.2
Background: The Asia-Pacific Breast Initiatives (APBI) I and II registries were established to collect safety data for patients with early stage breast cancer receiving adjuvant docetaxel-based regimens in the Asia-Pacific region. Materials and Methods: Data from the two registries were combined to perform a safety analysis. Participants in the registry were women with early stage operable breast cancer with an intermediate or high risk of recurrence. These women received adjuvant chemotherapy that included docetaxel between 2006 and 2011. Adverse events (AEs) were recorded and analyzed. Results: Data were collected from 3,224 patients from 13 countries. The mean dose intensity of docetaxel was 24.1, 22.7, $25.1mg/m^2/week$ among patients receiving docetaxel-based monotherapy, combination therapy and sequential therapy, respectively. Granulocyte colony-stimulating factor (G-CSF) was given with docetaxel to 41.8% of women and 20.6% of women receiving prophylactic antibiotics. Adverse events were reported in 86% of patients (anthracycline-containing regimens vs. non-anthracycline regimens; 87% vs. 80%). The most common adverse events were alopecia, nausea, neutropenia, vomiting, and myalgia. Adverse events NCI CTCAE ${\geq}$Grade 3 were reported in 45.4% of patients. Serious adverse events were reported in 13% of patients, of which 2.5% led to study discontinuation. Forty-six deaths (1.4%) were reported, with no significant difference between regimens. Conclusions: The safety parameters of adjuvant docetaxel therapy used to treat sequential Asian women were comparable to those reported in clinical trials evaluating the role of adjuvant docetaxel. No unusual adverse events linked to Asia-Pacific region patients were observed.